ABSTRACT
OBJECTIVE: To report the computed tomography (CT) features of acute cerebrovascular complications in severely ill patients with confirmed coronavirus disease 2019 (COVID-19) in the intensive care unit. MATERIALS AND METHODS: We conducted a retrospective analysis of 29 intensive care unit patients with confirmed COVID-19 who underwent CT of the brain. We describe the CT features of the cerebrovascular complications of COVID-19, as well the demographic characteristics and clinical features, together with the results of laboratory tests, such as complete blood cell count, coagulation testing, renal function testing, and C-reactive protein assay. RESULTS: Two patients were excluded because of brain death. Among the remaining 27 patients, CT revealed acute cerebrovascular complications in six (three men and three women; 49-81 years of age), whereas no such complications were seen in 21 (15 men and six women; 36-82 years of age). CONCLUSION: Radiologists should be aware of the risks of cerebrovascular complications of COVID-19 and the potential underlying etiologies. COVID-19-associated coagulopathy is likely multifactorial and may increase the risk of ischemic and hemorrhagic infarction.
OBJETIVO: Relatar as características da tomografia computadorizada (TC) das complicações cerebrovasculares agudas em pacientes com doença do coronavírus 2019 (COVID-19) grave, internados em unidade de terapia intensiva. MATERIAIS E MÉTODOS: Foi realizada análise retrospectiva de 29 pacientes com COVID-19 confirmada, internados em unidade de terapia intensiva, que realizaram TC de crânio. Descrevemos as alterações tomográficas das complicações cerebrovasculares, bem como as características demográficas, clínicas e exames laboratoriais, tais como hemograma completo, teste de coagulação, função renal e proteína C reativa desses pacientes. RESULTADOS: Seis pacientes (três homens e três mulheres; faixa etária de 49-81 anos) apresentaram alterações cerebrovasculares reveladas por TC e 21 pacientes (15 homens e 6 mulheres; faixa etária de 36-82 anos) não apresentaram complicações cerebrovasculares agudas. Dois pacientes foram excluídos por morte encefálica. CONCLUSÃO: Os radiologistas devem estar cientes dos riscos de complicações cerebrovasculares da COVID-19 e das possíveis etiologias subjacentes. A coagulopatia relacionada à COVID-19 é provavelmente multifatorial e pode aumentar os riscos de infarto isquêmico e hemorrágico.
ABSTRACT
Background: Convalescent plasma is a potential therapeutic option for critically ill patients with coronavirus disease 19 (COVID-19), yet its efficacy remains to be determined. The aim was to investigate the effects of convalescent plasma (CP) in critically ill patients with COVID-19. Methods: This was a single-center prospective observational study conducted in Rio de Janeiro, Brazil, from March 17th to May 30th, with final follow-up on June 30th. We included 113 laboratory-confirmed COVID-19 patients with respiratory failure. Primary outcomes were time to clinical improvement and survival within 28 days. Secondary outcomes included behavior of biomarkers and viral loads. Kaplan-Meier analyses and Cox proportional-hazards regression using propensity score with inverse-probability weighing were performed. Results: 41 patients received CP and 72 received standard of care (SOC). Median age was 61 years (IQR 48-68), disease duration was 10 days (IQR 6-13), and 86% were mechanically ventilated. At least 29 out of 41CP-recipients had baseline IgG titers ≥ 1:1,080. Clinical improvement within 28 days occurred in 19 (46%) CP-treated patients, as compared to 23 (32%) in the SOC group [adjusted hazard ratio (aHR) 0.91 (0.49-1.69)]. There was no significant change in 28-day mortality (CP 49% vs. SOC 56%; aHR 0.90 [0.52-1.57]). Biomarker assessment revealed reduced inflammatory activity and increased lymphocyte count after CP. Conclusions: In this study, CP was not associated with clinical improvement or increase in 28-day survival. However, our study may have been underpowered and included patients with high IgG titers and life-threatening disease. Clinical Trial Registration: The study protocol was retrospectively registered at the Brazilian Registry of Clinical Trials (ReBEC) with the identification RBR-4vm3yy (http://www.ensaiosclinicos.gov.br).